Serum thymidine kinase activity as a "real-time" clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer

被引：0
|
作者：
Bagegni, Nusayba
Williams, Amy
Grigsby, Isabella
Bergqvist, Mattias
Clifton, Katherine
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-15-06
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
    Martinez-Saez, O.
    Tolosa, P.
    Sanchez De Torre, A.
    Pascual, T.
    Braso-Maristany, F.
    Rodriguez Hernandez, A.
    Parrilla, L.
    Roncero, A. M.
    Ruano, Y.
    Chic, N.
    Schettini, F.
    Laguna, J. C.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Vidal, M.
    Adamo, B.
    Guillen Sacoto, M. C.
    Munoz, M.
    Prat, A.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S30 - S30
  • [22] Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
    Malorni, L.
    De laurentiis, M.
    Bianchini, G.
    Zambelli, A.
    Puglisi, F.
    Bianchi, G. V.
    Del Mastro, L.
    Paris, I.
    Montemurro, F.
    Allegrini, G.
    Colleoni, M. A.
    Tamberi, S.
    Zamagni, C.
    Cazzaniga, M. E.
    Orditura, M.
    Guarneri, V.
    Castelletti, D.
    Benelli, M.
    Di Marino, M.
    Arpino, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S492 - S492
  • [23] Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)
    Xi, Jing
    Bagegni, Nusayba
    Ademuyiwa, Foluso
    Frith, Ashley
    Suresh, Rama
    Roshal, Anna
    Rigden, Caron
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Opyrchal, Mateusz
    Clifton, Katherine
    Weilbaecher, Katherine
    Bose, Ron
    Ma, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
  • [24] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [25] Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
    Schettini, Francesco
    Palleschi, Michela
    Mannozzi, Francesca
    Braso-Maristany, Fara
    Cecconetto, Lorenzo
    Galvan, Patricia
    Mariotti, Marita
    Ferrari, Alessia
    Scarpi, Emanuela
    Miserocchi, Anna
    Nanni, Oriana
    Sanfeliu, Esther
    Prat, Aleix
    Rocca, Andrea
    De Giorgi, Ugo
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [27] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [28] Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer
    Sanchez-Bayona, Rodrigo
    Teran, Santiago
    De Torre, Ana Sanchez
    Alva, Manuel
    Lema, Laura
    Manso, Luis
    Toledo, Estefania
    Roncero, Ana Maria
    Merino, Cristina
    Martinez, Mario
    Parrilla, Lucia
    Ciruelos, Eva
    Tolosa, Pablo
    CANCER RESEARCH, 2022, 82 (04)
  • [29] Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
    Zhang, Cui
    Zhou, Fulin
    Zou, Jiali
    Fang, Yanman
    Liu, Yuncong
    Li, Libo
    Hou, Jing
    Wang, Guanghui
    Wang, Hua
    Lai, Xiaolian
    Xie, Lu
    Jiang, Jia
    Yang, Can
    Huang, Yisidan
    Chen, Yingji
    Zhang, Hanqun
    Li, Yong
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [30] CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohort
    Javaid, Anadil
    Lok, Sheau Wen
    Wong, Vanessa
    Baron-Hay, Sally
    Boyle, Fran
    Collins, Ian
    Cuff, Katharine
    de Boer, Richard
    Gately, Lucy
    Georgiou, Chloe
    Greenberg, Sally
    Karki, Bhaskar
    Nottage, Michelle
    Rainey, Natalie
    Torres, Javier
    Yeo, Belinda
    Devitt, Bianca
    Gibbs, Peter
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 129 - 130
12345